An FDA-Cleared Gastrointestinal Test to Distinguish IBS from IBD
The Calprotectin gastrointestinal test effectively distinguishes Irritable Bowel Syndrome (IBS) from Inflammatory Bowel Disease (IBD). IBS and IBD often cause similar symptoms of abdominal pain, cramping, and chronic diarrhea, making an accurate diagnosis difficult. Calprotectin reliably differentiates IBS from IBD using a patient-friendly, non-invasive, stool test.
Why use the Calprotectin test?
An invasive endoscopic/biopsy procedure is the gold-standard test used for patients presenting with symptoms that could indicate IBD. However, many patients undergoing invasive procedures are ultimately diagnosed with IBS, a non-inflammatory, functional disorder. Calprotectin offers several advantages:
- Fecal Calprotectin is an FDA-cleared stool test for differentiating IBS from IBD
- Calprotectin is an indicator of inflammation, which is commonly associated with IBD and other inflammatory conditions
- Fecal Calprotectin is described in the scientific literature to be a useful screening tool for identifying which patients may need endoscopy
- It is also described to be useful for quantifying the degree of inflammation, monitoring treatment, and assessing for relapse in IBD
Treatments guided by the use of fecal Calprotectin may reduce rates of invasive gastrointestinal procedures, unnecessary office visits, and therapeutic trials of prescription drugs that are often ineffective in patients with IBS.
Calprotectin may be ordered as a single test and is also an included biomarker on the GI Effects® Comprehensive Stool Profile, a more complete assessment of overall gastrointestinal health
Learn more about the GI Effects® Comprehensive Stool Profile.